|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis显示文摘AIM:To review the current literature for the specificclinical characteristics of inflammatory bowel disease(IBD)associated with primary sclerosing cholangitis(PSC).METHODS:A systematical review for clinical characteristics of IBD in PSC was performed by conducting a broad search for'primary sclerosing cholangitis'in Pubmed.'Clinical characteristics'were specified into five predefined subthemes:epidemiology of IBD in PSC,characteristics of IBD in PSC(i.e.,location,disease behavior),risk of colorectal cancer development,IBD recurrence and de novo disease after liver transplantation for PSC,and safety and complications after proctocolectomy with ileal pouchanal anastomosis.Papers were selected for inclusion based on their relevance to the subthemes,and were reviewed by two independent reviewers.Only full papers relevant to PSC-IBD were included.Additionally the references of recent reviews for PSC(<5 years old)were scrutinized for relevant articles.RESULTS:Initial literature search for PSC yielded 4704results.After careful review 65 papers,comprising a total of 11406 PSC-IBD patients,were selected and divided according to subtheme.Four manuscripts overlapped and were included in two subthemes.Prevalence of IBD in PSC shows a large variance,ranging from 46.5%to 98.7%with ulcerative colitis(UC)being the most common type(>75%).The highest IBD rates in PSC are found in papers reviewing both endoscopic and histological data for IBD diagnosis.Although IBD in PSC is found to be a quiescent disease,pancolitis occurs often,with rates varying from 35%to 95%.Both backwash ileitis and rectal sparing are observed infrequently.The development of dysplasia or colorectal carcinoma is increased in PSC-IBD;the cumulative 10 years risk varying between 0%and11%.Exacerbation of IBD is common after liver transplantation for PSC and de novo disease is seen in1.3%to 31.3%of PSC-IBD patients.The risk for development of pouchitis in PSC-IBD is found to besignificant,affecting 13.8%to 90%of the patients after proctocolectomy with ileo anal-pouch anastomosis.CONCLUSION:IBD in primary sclerosing cholangitis represents a distinct phenotype that differs from UC and Crohn’s disease and therefore requires specialized management. | A Boudewijn de Vries Marcel Janse Hans Blokzijl Rinse K Weersma | 2015 | World Journal of Gastroenterology2015，21，6： | 17 |
| 2 | Diagnostic yield of small bowel capsule endoscopy depends on the small bowel transit time显示文摘AIM:To investigate whether the small bowel transit time(SBTT)influences the diagnostic yield of capsule endoscopy(CE).METHODS:Six hundred and ninety-one consecutive CE procedures collected in a database were analyzed.SBTT and CE findings were recorded.A running mean for the SBTT was calculated and correlated to the diagnostic yield with a Spearman's correlation test.Subgroup analyses were performed for the various indications for the procedure.RESULTS:There was a positive correlation between the diagnostic yield and SBTT(Spearman's rho 0.58,P <0.01).Positive correlations between diagnostic yield and SBTT were found for the indication obscure gastrointestinal bleeding(r=0.54,P<0.01),for polyposis and carcinoid combined(r=0.56,P<0.01)and for the other indications(r=0.90,P<0.01),but not for suspected Crohn's disease(r=-0.40).CONCLUSION:The diagnostic yield in small bowel capsule endoscopy is positively correlated with the small bowel transit time.This is true for all indications except for suspected Crohn's disease. | Jessie Westerhof Jan J Koornstra Reinier A Hoedemaker Wim J Sluiter Jan H Kleibeuker Rinse K Weersma | 2012 | World Journal of Gastroenterology2012，18，13： | 10 |
| 3 | Pharmacomicrobiomics: a novel route towards personalized medicine?显示文摘在药反应的内部个人的异质是影响病人幸福并且在社会水平上提出庞大的临床、金融的负担的一个严重问题。Pharmacogenomics 在关于药反应可变性或药毒性的对单个基因背景的影响的研究的最前线,并且最近,内脏 microbiome,也被称为第二个染色体,在这个方面作为一个重要播放器被认出了。而且, microbiome 是为由于机会改进药功效和安全操作它的作文的一个很吸引人的目标。Pharmacomicrobiomics 是调查 microbiome 变化和药反应和布置(吸收,分发,新陈代谢和排泄) 的相互影响的一个新兴的领域。在这评论,我们提供历史的概述并且在在内脏 microbiome,主人和药之间的复杂相互作用上检验当前的最先进的知识。我们主张那联合 pharmacogenomics 和 pharmacomicrobiomics 将为在个性化的药做主要进展提供一个重要基础。 | Marwah Doestzada Arnau Vich Vila Alexandra Zhernakova Debby P.Y. Koonen Rinse K. Weersma Daan J. TOUW Folkert Kuipers Cisca Wijmenga Jingyuan Fu | 2018 | Protein & Cell2018，9，5： | 7 |
| 4 | Management of rectal foreign bodies: Description of a new technique and clinical practice guidelines显示文摘A number of techniques have been described to remove rectal foreign bodies. In this report, a novel endoscopic technique using a pneumatic dilatation balloon normally used in achalasia patients is presented. In addition, a systematic review of the literature was performed for non-operative methods to remove foreign bodies from the rectum. These results are summarised, presented as a practical at-a- glance overview and a flow chart is offered to guide the clinician in treatment decisions. The design of the flow chart was based on the aims to treat the patient preferably on an outpatient basis with minimally invasive techniques and if possible under conscious sedation rather than general anaesthesia. | Jan J Koornstra Rinse K Weersma | 2008 | World Journal of Gastroenterology2008，14，27： | 5 |
| 5 | Performance of the Montreal classification for inflammatory bowel diseases显示文摘AIM:To validate the Montreal classification system for Crohn's disease(CD) and ulcerative colitis(UC) within the Netherlands.METHODS:A selection of 20 de-identified medical records with an appropriate representation of the inflammatory bowel disease(IBD) sub phenotypes were scored by 30 observers with different professions(gastroenterologist specialist in IBD,gastroenterologist in training and IBD-nurses) and experience level with IBD patient care.Patients were classified according to the Montreal classification.In addition,participants were asked to score extra-intestinal manifestations(EIM) and disease severity in CD based on their clinical judgment.The inter-observer agreement was calculated by percentages of correct answers(answers identical to the 'expert evaluation') and Fleiss-kappa(k).Kappa cutoffs:< 0.4-poor; 0.41-0.6-moderate; 0.61-0.8-good; > 0.8 excellent.RESULTS:The inter-observer agreement was excellent for diagnosis(k = 0.96),perianal disease(k = 0.92) and disease location in CD(k = 0.82) and good for age of onset(k = 0.67),upper gastrointestinal disease(k = 0.62),disease behaviour in CD(k = 0.79) and disease extent in UC(k = 0.65).Disease severity in UC was scored poor(k = 0.23).The additional items resulted in a good inter-observer agreement for EIM(k = 0.68) and a moderate agreement for disease severity in CD(k = 0.44).Percentages of correct answers over all Montreal items give a good reflection of the inter-observer agreement(> 80%),except for disease severity(48%-74%).IBD-nurses were significantly worse in scoring upper gastrointestinal disease in CD compared to gastroenterologists(P = 0.008) and gastroenterologists in training(P = 0.040).Observers with less than 10 years of experience were significantly better at scoring UC severity than observers with 10-20 years(P = 0.003) and more than 20 years(P = 0.003) of experience with IBD patient care.Observers with 10-20 years of experience with IBD patient care were significantly better at scoring upper gastrointestinal disease in CD than observers with less than 10 years(P = 0.007) and more than 20 years(P = 0.007) of experience with IBD patient care.CONCLUSION:We found a good to excellent interobserver agreement for all Montreal items except for disease severity in UC(poor). | Lieke M Spekhorst Marijn C Visschedijk Rudi Alberts Eleonora A Festen Egbert-Jan van der Wouden Gerard Dijkstra Rinse K Weersma | 2014 | World Journal of Gastroenterology2014，20，41： | 4 |
| 6 | Predicting(side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics显示文摘Inflammatory bowel disease (IBD) is a chronic and heterogeneous intestinal inflammatory disorder. The medical management of IBD aims for long-lasting disease remission to prevent complications and disease progression. Early introduction of immunosuppression forms the mainstay of medical IBD management. Large inter-individual variability in drug responses, in terms of both efficacy and toxicity, leads to high rates of therapeutic failure in the management of IBD. Better patient stratification is needed to maximize patient benefit and minimize the harm caused by adverse events. Pre-treatment pharmacogenetic testing has the potential to optimize drug selection and dose, and to minimize harm caused by adverse drug reactions. In addition, optimizing the use of cheap conventional drugs, and avoiding expensive ineffective drugs, will lead to a significant reduction in costs. Genetic variation in both TPMT and NUDT15, genes involved in thiopurine metabolism, is associated to an increased risk of thiopurine-induced myelosuppression. Moreover, specific HLA haplotypes confer risk to thiopurine-induced pancreatitis and to immunogenicity to tumor necrosis factor-antagonists, respectively. Falling costs and increased availability of genetic tests allow for the incorporation of pre-treatment genetic tests into clinical IBD management guidelines. In this paper, we review clinically useful pharmacogenetic associations for individualized treatment of patients with IBD and discuss the path from identification of a predictive pharmacogenetic marker to implementation into IBD clinical care. | Michiel Dirk Voskuil Amber Bangma Rinse Karel Weersma Eleonora Anna Margaretha Festen | 2019 | World Journal of Gastroenterology2019，25，21： | 2 |
| 7 | How will insights from genetics translate to clinical practice in inflammatory bowel disease?显示文摘 | E.A.M. Festen R.K. Weersma | 2014 | Best Practice & Research Clinical Gastroenterology2014，，3： | 2 |
| 8 | Risk factors for incomplete small-bowel capsule endoscopy显示文摘 | Westerhof J Weersma RK Koornstra JJ | 2009 | Gastrointest Endosc2009，69，1： | 1 |
| 9 | Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases显示文摘 | Weersma RK Peters FT Oostenbrug LE | 2004 | Aliment Pharmacol Ther2004，20，8： | 1 |
| 10 | Treatmenl of complexbillaD' stones by eholangioseopy laser litho/ripsy in 10 patients显示文摘 | Verdonk RC de Ruiter A J Weersma RK | 2010 | Ned TijdschrGeneeskd2010，154，： | 1 |
| 11 | Host-microbe in-teractions have shaped the genetic architecture of inflam-matory bowel disease 显示文摘 | Jostins L Ripke S Weersma RK | 2012 | Nature2012，491，7422： | 1 |
| 12 | Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci显示文摘 | Trine Folseraas Espen Melum Philipp Rausch Brian D. Juran Eva Ellinghaus Alexey Shiryaev Jon K. Laerdahl David Ellinghaus Christoph Schramm Tobias J. Weismüller Daniel Nils Gotthardt Johannes Roksund Hov Ole Petter Clausen Rinse K. Weersma Marcel Janse Ki | 2012 | Journal of Hepatology2012，，2： | 1 |
| 13 | Host -mi- crobe interactions have shaped the genetic architecture of inflammatory bowel disease 显示文摘 | Jostins L Ripke S Weersma R K | 2012 | Nature2012，491，7422： | 1 |
| 14 | Investigating obscure gastrointes- tinal bleeding: capsule endoscopy or double balloon enteroscopy? 显示文摘 | Westerhof J Weersma RK Koornstra JJ | 2009 | Neth J Med2009，67，7： | 1 |
| 15 | Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease显示文摘 | de Ridder L Weersma RK Dijkstra G | 2007 | Inflamm Bowel Dis2007，13，9： | 1 |
| 16 | Treatment of severe ulcerative colitis显示文摘 | Weersma RK Van Dullernen HM | 2006 | Ned Tijdschr Geneeskd2006，150，1： | 1 |
| 17 | Association of interleukin-1 receptor-associated kinase M ( IRAK-M ) and inflammatory bowel diseases 显示文摘 | Weersma RK Oostenbrug LE Nohe IM | 2007 | Scand J Gastroenterol2007，42，7： | 1 |
| 18 | Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease显示文摘 | Jostins L Ripke S Weersma RK | 2012 | Nature2012，491，7422： | 1 |
| 19 | Association of Crohn's disease-associated NOD2 variants with intestinal failure requiring small bowel transplantation and clinical outcomes显示文摘 | JANSE M WEERSMA R K SUDAN D L | | 0，，06： | 1 |
| 20 | Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis显示文摘 | Kirsten Boonstra Rinse K. Weersma Karel J. Erpecum Erik A. Rauws B.W. Marcel Spanier Alexander C. Poen Karin M. Nieuwkerk Joost P. Drenth Ben J. Witteman Hans A. Tuynman Anton H. Naber Paul J. Kingma Henk R. Buuren Bart Hoek Frank P. Vleggaar Nan Geloven | 2013 | Hepatology2013，，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员